Castle Biosciences Revenue

In the year 2025, Castle Biosciences had annual revenue of $344.23M with 3.66% growth. Castle Biosciences had revenue of $87.01M in the quarter ending December 31, 2025, with 0.81% growth.

Revenue (ttm)

$344.23M

Revenue Growth

+3.66%

P/S Ratio

2.17

Revenue / Employee

$389,840

Employees

883

Market Cap

748.01M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	344.23M	12.16M	3.66%
Dec 31, 2024	332.07M	112.28M	51.09%
Dec 31, 2023	219.79M	82.75M	60.38%
Dec 31, 2022	137.04M	42.95M	45.65%
Dec 31, 2021	94.09M	31.44M	50.18%
Dec 31, 2020	Pro	Pro	Pro
Dec 31, 2019	Pro	Pro	Pro
Dec 31, 2018	Pro	Pro	Pro
Dec 31, 2017	Pro	Pro	Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Myriad Genetics	824.50M
NeoGenomics	727.33M
OPKO Health	606.88M
Veracyte	517.15M
GeneDx Holdings	427.54M
CareDx	379.81M
Fulgent Genetics	322.67M
GRAIL	147.17M

Revenue Rankings

CSTL News

8 days ago - Castle Biosciences to Present New Data Demonstrating DecisionDx®-Melanoma's Ability to Identify Patients with Greater Risk of Recurrence and Poor Outcomes Within Early-Stage Melanoma at EADO and ACMS - PRNewsWire
14 days ago - Castle Biosciences to Release First Quarter 2026 Financial Results and Host Webcast on Wednesday, May 6, 2026 - PRNewsWire
19 days ago - Castle Biosciences Earns 2026 USA TODAY Top Workplaces Award for Fifth Consecutive Year - PRNewsWire
4 weeks ago - Castle Biosciences' DecisionDx®-Melanoma Test Significantly Improves Risk Prediction Within AJCC Stages to Support Personalized, Risk-Aligned Management of Cutaneous Melanoma, Data to Be Presented at AAD 2026 - PRNewsWire
5 weeks ago - Castle Biosciences Transcript: Status update - Transcripts
6 weeks ago - Prospective, Multi-center Study Published in Future Oncology Demonstrates DecisionDx®-Melanoma's i31-SLNB Result Outperforms Staging Criteria in Identifying Patients with Cutaneous Melanoma Below the 5% NCCN Threshold for Forgoing SLNB - GlobeNewsWire
7 weeks ago - DecisionDx®-Melanoma's i31-SLNB: Report from the Largest Prospective Multicenter Study to Date Confirms 2.6% Nodal Positivity in Patients Predicted to Have Less Than 5% Risk - GlobeNewsWire
7 weeks ago - Castle Biosciences to Present Data at SSO 2026 on DecisionDx®-Melanoma's i31-SLNB, Identifying T1b–T2a Melanoma Patients Who May Safely Avoid SLNB - GlobeNewsWire

More News